Articles Accepted

A novel simple and rapid reverse phase high performance liquid chromatography (RP-HPLC) method has been developed and validated for estimation of Bexarotene, an antineoplastic drug used orally and topically for effective treatment of Cutaneous–T-Cell Lymphoma. Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). The developed method was validated as per guidelines of ICH. RP-HPLC was derived out on a Shimadzu binary C18 (250 mm x 4.6 mm, 5μm) column with a mobile phase of Acetonitrile and Ammonium Acetate Buffer (pH 4.1) in the ratio of 75:25 v/v. The 20 μl standard and sample was injected with the flow rate of 1.0 ml/minute. The detection wavelength at PDA detector was carried out at 264 nm. The retention time is 7.0 minutes for Bexarotene. The linearity was found in the range of 10-100 μg/ml with correlation coefficient of 0.998. The percent recoveries found were in the range of 85.33-101.87%.